The use of systemic steroids and photodynamic treatment for choroidal neovascularisation in young patients

Advantages of adjunctive corticosteroid treatment in combination with photodynamic treatment (PDT) as against PDT alone in eyes with subfoveal idiopathic choroidal neovascularisatio

Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy

PURPOSE: To assess the visual and anatomic outcomes of central serous chorioretinopathy (CSC) after verteporfin photodynamic therapy (PDT). DESIGN: Retrospective case series. PARTICIPANTS: Patients with CSC who underwent PDT. METHODS: Members of the Macula Society were surveyed to retrospectively collect data on PDT treatment for CSC. Patient demographic information, PDT treatment parameters, fluorescein angiographic information, optical coherence tomography (OCT) metrics, pre- and post-treatment visual acuity (VA), and adverse outcomes were collected online using standardized forms. MAIN OUTCOME MEASURES: Visual acuities over time and presence or absence of subretinal fluid (SRF). RESULTS: Data were submitted on 265 eyes of 237 patients with CSC with a mean age of 52 (standard deviation [+/- 11]) years; 61 were women (26%). Mean baseline logarithm of the minimum angle of resolution (logMAR) VA was 0.39+/-0.36 (20/50). Baseline VAs were \u3e/=20/32 in 115 eyes (43%), 20/40 to 20/80 in 97 eyes (37%), and/=3 lines in/=20/32, 20/40 to 20/80, and0.01). Complications were rare: Retinal pigment epithelial atrophy was seen in 4% of patients, and acute severe visual decrease was seen in 1.5% of patients. CONCLUSIONS: Photodynamic therapy was associated with improved VA and resolution of SRF. Adverse side effects were rare

North Carolina macular dystrophy (MCDR1) locus: a fine resolution genetic map and haplotype analysis

We previously reported linkage of North Carolina macular dystrophy in a single isolated family to a broad region on chromosome 6q16. In order to refine the localization of the MCDR1 gene (North Carolina macular dystrophy), additional families with this disease and new markers were studied.We ascertained 10 families with the North Carolina macular dystrophy phenotype (MCDR1). These families were of various ethnic and geographic origins such as Caucasian, Mayan Indian, African-American, French, British, German, and American of European decent. Two hundred thirty-two individuals in these families underwent comprehensive ophthalmic examinations and blood was collected for genotyping. One hundred seventeen were found to be affected. Linkage simulation studies were performed. Two-point linkage, haplotype analysis, and multipoint linkage was performed using VITESSE and FASTLINK. HOMOG was used to test for genetic heterogeneity.The clinical features were consistent with the diagnosis of North Carolina macular dystrophy in all families. Multipoint linkage analysis indicates that the MCDR1 gene is in the interval between D6D249 and D6S1671 with a maximum LOD score of 41.52. There was no evidence of genetic heterogeneity among the families studied. Families 765, 768, 772, 1193, and 1292 shared the same chromosomal haplotype in this region.This is the largest single data set of families with the MCDR1 phenotype. The single large family from North Carolina continues to be informative for the closest flanking markers and alone supports the minimal candidate region as suggested by previous studies. There remains no evidence of genetic heterogeneity in this disease. Most of the American families appear to have descended from the same ancestral mutation. The remaining families could each represent independent origins of the mutation in the MCDR1 gene

Bromfenac Eyedrops in the Treatment of Diabetic Macular Edema: A Pilot Study

PurposeTo evaluate the efficacy and safety of topical bromfenac in patients with newly diagnosed diabetic macular edema (DME).MethodsIn this pilot study including 17 patients with monocular, newly ..